We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Long-term follow-up of high-dose treatment with autologous haematopoietic progenitor cell support in 693 patients with follicular lymphoma: an EBMT registry study.
- Authors
Montoto, S.; Canals, C.; Rohatiner, A. Z. S.; Taghipour, G.; Sureda, A.; Schmitz, N.; Gisselbrecht, C.; Fouillard, L.; Milpied, N.; Haioun, C.; Slavin, S.; Conde, E.; Fruchart, C.; Ferrant, A.; Leblond, V.; Tilly, H.; Lister, T. A.; Goldstone, A. H.
- Abstract
To evaluate the outcome of a large series of patients who received high-dose treatment (HDT) for follicular lymphoma (FL), 693 patients undergoing HDT (total-body irradiation (TBI)-containing regimen: 58%; autologous bone marrow (BM)/peripheral blood progenitor cells (PBPCs): 378/285 patients) were included in the study. A total of 375 patients (54%) developed recurrent lymphoma, 10-year progression-free survival (PFS) being 31%. On multivariate analysis, younger age (P=0.003) and HDT in first complete remission (CR1) (P<0.001) correlated with longer PFS. With a median follow-up of 10.3 years, 330 patients died. Ten-year overall survival (OS) from HDT was 52%. Shorter OS was associated on multivariate analysis with older age (P<0.001), chemoresistant disease (P<0.001), BM+PBPC as source of stem cells (P=0.007) and TBI-containing regimens (P=0.004). Thirty-nine patients developed secondary myelodysplastic syndrome/acute myeloid leukaemia (MDS/AML), in 34 cases having received TBI as the conditioning regimen. The 5-year non-relapse mortality (NRM) was 9%. On multivariate analysis, older age (P<0.001), refractory disease (P<0.001) and TBI (P=0.04) were associated with a higher NRM. This long follow-up study shows a plateau in the PFS curve, suggesting that a selected group of patients might be cured with HDT. On the downside, TBI-containing regimens are associated with a negative impact on survival.Leukemia (2007) 21, 2324–2331; doi:10.1038/sj.leu.2404850; published online 19 July 2007
- Subjects
HEMATOPOIETIC agents; DRUG dosage; LYMPHOMAS; MYELODYSPLASTIC syndromes; MULTIVARIATE analysis; STEM cells
- Publication
Leukemia (08876924), 2007, Vol 21, Issue 11, p2324
- ISSN
0887-6924
- Publication type
Article
- DOI
10.1038/sj.leu.2404850